Goserelin: Uses, Mechanism, and Side Effects

Anyone starting hormone therapy for prostate or breast cancer, or considering treatment for endometriosis, wants to know what the drug does and how it has performed in practice. Goserelin is a long-studied hormonal agent with a well-documented label and an extensive clinical trial history.

Key takeaways

• Goserelin is a synthetic GnRH agonist sold under the brand name Zoladex.
• It is approved for prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning before ablation.
• More than 435 trials have been registered involving this compound.
• Reported adverse events are dominated by terms tied to underlying cancer progression, such as death and malignant neoplasm progression, alongside fatigue and neutropenia.
• Its molecular identity is catalogued under PubChem CID 5311128.

What Goserelin Is

Goserelin is a synthetic decapeptide that mimics gonadotropin releasing hormone (GnRH). When delivered in its biodegradable formulation, it suppresses the pituitary gland's release of gonadotropins. This action lowers the body's production of sex hormones, which is the basis for its use in hormone-sensitive conditions. Laboratory and animal research has shown that goserelin can slow or shrink hormone-sensitive tumor growth.

What Goserelin Is Approved For

Under the brand name Zoladex, goserelin carries several approved uses. It is indicated in combination with flutamide for locally confined prostate carcinoma, specifically Stage T2b-T4 disease, with treatment starting eight weeks before radiation therapy. It is also approved for palliative treatment of advanced prostate carcinoma, for management of endometriosis, as an endometrial-thinning agent before endometrial ablation for dysfunctional uterine bleeding, and for palliative treatment of advanced breast cancer in pre- and perimenopausal women. The label does not carry a boxed warning.

What the Evidence Shows

More than 435 trials have been registered that involve goserelin, reflecting decades of clinical use across its approved indications. Among the sampled studies, a completed Phase 2 trial examined tecemotide alongside prostate cancer treatment, and a completed Phase 4 trial compared switching from Zoladex dosing schedules to a different depot formulation. A newer study is planned to evaluate radiation therapy combined with androgen deprivation therapy, though it has not yet begun recruiting.

Reported Side Effects

Adverse event reports linked to goserelin are frequent, which reflects its long history of use in serious cancer indications rather than a specific safety signal. These are report counts, not confirmed incidence rates or evidence of causation. The most commonly reported terms include death and malignant neoplasm progression, both of which likely reflect the advanced disease state of many patients treated with this drug. Other frequently reported reactions include fatigue, metastases to bone, neutropenia, nausea, hot flush, and asthenia.